News
US clinical-stage biotech ProKidney reported statistically-significant and clinically-meaningful positive top-line results ...
ProKidney shares surged 500% on positive Phase 2 CKD results. Read why I remain cautious about PROK stock despite the recent ...
The company also encounters competitive risks from other organizations developing therapies for chronic kidney disease.
ProKidney stock jumps after Phase 2 trial shows rilparencel significantly slowed kidney function decline in patients with ...
ProKidney shares soar on promising Rilparencel mid-stage data for chronic kidney disease. But PROK stock remains a high-risk ...
(PROK) stock soars 56% after positive mid-stage trial results for the company's lead drug rilparencel in chronic kidney ...
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company ...
ProKidney shares jumped 56% in premarket trading after reporting positive topline results from a select population group in a Phase 2 trial evaluating rilparencel in patients with chronic kidney ...
At one point, ProKidney had been running an international phase 3 trial, dubbed PROACT 2, of rilparencel alongside the ...
Shares of ProKidney rose 558% after it reported favorable results from a study of its lead drug candidate, rilparencel, in patients with chronic kidney disease and diabetes.
A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results